918 related articles for article (PubMed ID: 31199090)
21. Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.
Weaver SB; Akinwale H; Nonyel NP; Wingate LT
Expert Rev Hematol; 2024 Jun; 17(6):255-260. PubMed ID: 38753522
[TBL] [Abstract][Full Text] [Related]
22. Real-world data on voxelotor to treat patients with sickle cell disease.
Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
[TBL] [Abstract][Full Text] [Related]
23. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Çanak B; Eşkazan AE
Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
[No Abstract] [Full Text] [Related]
24. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
25. Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease.
Keipert PE;
Adv Exp Med Biol; 2016; 923():23-29. PubMed ID: 27526120
[TBL] [Abstract][Full Text] [Related]
26. Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
Shet AS; Mendelsohn L; Harper J; Ostrowski D; Henry ER; Gwaabe E; Nichols J; Alayash AI; Eaton WA; Thein SL
Am J Hematol; 2019 Apr; 94(4):E88-E90. PubMed ID: 30592074
[No Abstract] [Full Text] [Related]
27. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
28. A "Split" Hemoglobin S Peak.
Colby JM; Shajani-Yi Z
Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
[No Abstract] [Full Text] [Related]
29. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
30. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action.
Suhail M
Sci Rep; 2024 Jan; 14(1):1861. PubMed ID: 38253605
[TBL] [Abstract][Full Text] [Related]
31. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
32. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
33. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
Lemon N; Sterk E; Rech MA
Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907
[TBL] [Abstract][Full Text] [Related]
34. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
35. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
Minniti CP; Knight-Madden J; Tonda M; Gray S; Lehrer-Graiwer J; Biemond BJ
Am J Hematol; 2021 Apr; 96(4):E126-E128. PubMed ID: 33476432
[No Abstract] [Full Text] [Related]
36. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
37. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
39. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
40. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]